Paper41385341
Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.
Meyer EH and 25 others. Blood, 2026. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Papers, record 41385341. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41385341
- Disease
- myelodysplastic syndrome421 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hematopoietic Stem Cell Transplantation | Major topic |
| Graft vs Host Disease | Major topic |
| Myelodysplastic Syndromes | Major topic |
| Leukemia | Major topic |
| Humans | |
| Male | |
| Adult | |
| Middle Aged | |
| Female | |
| Transplantation, Homologous | |
| Aged | |
| Methotrexate | |
| Young Adult | |
| Transplantation Conditioning | |
| Adolescent | |
| Tacrolimus |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed |
Source NIH RePORTER
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT05316701 | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | Results | Yes | ClinicalTrials.gov |
| NCT07346105 | Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 41817555 | Graft manipulation and GVHD: what goes around comes around. | https://conductscience.org/library/papers/41817555 |
Source PubMed
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29171820 | Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. | N Engl J Med | 2017 | https://conductscience.org/library/papers/29171820 | PubMed |
| 2 | 37330731 | Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis. | Cytotherapy | 2023 | https://conductscience.org/library/papers/37330731 | PubMed |
| 3 | 31023346 | Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). | J Hematol Oncol | 2019 | https://conductscience.org/library/papers/31023346 | PubMed |
| 4 | 26563133 | Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. | Blood | 2016 | https://conductscience.org/library/papers/26563133 | PubMed |
| 5 | 17095616 | In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. | Blood | 2007 | https://conductscience.org/library/papers/17095616 | PubMed |
| 6 | 26735993 | Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. | N Engl J Med | 2016 | https://conductscience.org/library/papers/26735993 | PubMed |
| 7 | 29423053 | Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. | Oncotarget | 2018 | https://conductscience.org/library/papers/29423053 | PubMed |
| 8 | 31092732 | Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. | JCI Insight | 2019 | https://conductscience.org/library/papers/31092732 | PubMed |
| 9 | 15994282 | Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. | Blood | 2005 | https://conductscience.org/library/papers/15994282 | PubMed |
| 10 | 33646302 | Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia. | Blood Adv | 2021 | https://conductscience.org/library/papers/33646302 | PubMed |
| 11 | 42628650 | Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients. | Transplant Cell Ther | 2026 | https://conductscience.org/library/papers/42628650 | PubMed |
| 12 | 37342922 | Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37342922 | PubMed |
| 13 | 26386318 | International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. | Biol Blood Marrow Transplant | 2016 | https://conductscience.org/library/papers/26386318 | PubMed |
| 14 | 34855460 | Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/34855460 | PubMed |
| 15 | 25994967 | Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease. | J Immunol | 2015 | https://conductscience.org/library/papers/25994967 | PubMed |
| 16 | 29040031 | Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/29040031 | PubMed |
| 17 | 12925844 | CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. | Nat Med | 2003 | https://conductscience.org/library/papers/12925844 | PubMed |
| 18 | 28395942 | Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy. | Cytotherapy | 2017 | https://conductscience.org/library/papers/28395942 | PubMed |
| 19 | 24415540 | Intravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD. | Blood | 2014 | https://conductscience.org/library/papers/24415540 | PubMed |
| 20 | 40398621 | Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR. | Transplant Cell Ther | 2025 | https://conductscience.org/library/papers/40398621 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42920839 | Regulatory T cell heterogeneity: who they are, where they come from, and where they go. | Front Immunol | 2026 | https://conductscience.org/library/papers/42920839 | PubMed |
| 42753097 | Orca-T: First Approval. | Mol Diagn Ther | 2026 | https://conductscience.org/library/papers/42753097 | PubMed |
| 42739525 | Indications for Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation in Adults: State of the Art. | J Clin Med | 2026 | https://conductscience.org/library/papers/42739525 | PubMed |
| 42344227 | CD8 regulatory T cell therapy in transplantation: a new path to clinical success? | Transpl Int | 2026 | https://conductscience.org/library/papers/42344227 | PubMed |
| 42060316 | Boosting "Treg-ulation": a good way to treat chronic GVHD? | Blood Adv | 2026 | https://conductscience.org/library/papers/42060316 | PubMed |
| 41758930 | Regulatory-like FOXP3+Helios+CD4+ T conventional cells correlate with T-cell activation after Orca-T immunotherapy. | Blood | 2026 | https://conductscience.org/library/papers/41758930 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| TACROLIMUS | CHEMBL3989887 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL3989887 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41385341
GET https://conductscience.org/api/papers/v1/41385341/authors?page=2